Research & KnowledgeEvent: September 2, 2026
Precision Epigenomics published the results of a new study showing EPISEEK outperforms alternative liquid biopsy tests across the board in sensitivity, specificity, and turnaround time.
Published
Signal category
Research & Knowledge
Quote
“Today, we are proud to announce the results of our new study. If you are evaluating MCED solutions for your practice or health system, the data are clear-cut: EPISEEK is outperforming alternative liquid biopsy tests across the board.”
— Precision Epigenomics team
Company
Precision Epigenomics
Advanced Solutions to Early Cancer Diagnostics
- Industry
- Medical and Diagnostic Laboratories
- Location
- Tucson, US
- Company size
- 31 employees